| Literature DB >> 29420224 |
Katherine C Kurnit1, Ecaterina E Ileana Dumbrava2, Beate Litzenburger3,4, Yekaterina B Khotskaya3, Amber M Johnson3, Timothy A Yap2, Jordi Rodon2, Jia Zeng3, Md Abu Shufean3, Ann M Bailey3, Nora S Sánchez3, Vijaykumar Holla3, John Mendelsohn3,5, Kenna Mills Shaw3, Elmer V Bernstam6, Gordon B Mills3,7, Funda Meric-Bernstam8,3,9.
Abstract
With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular characteristics of a patient's tumor, and an increasing number of trials are genomically selected. Furthermore, multiple studies have demonstrated the benefit of therapies that are chosen based upon the molecular profile of a tumor. However, the rapid evolution of genomic testing platforms and emergence of new technologies make interpreting molecular testing reports more challenging. More sophisticated precision oncology decision support services are essential. This review outlines existing tools available for health care providers and precision oncology teams and highlights strategies for optimizing decision support. Specific attention is given to the assays currently available for molecular testing, as well as considerations for interpreting alteration information. This article also discusses strategies for identifying and matching patients to clinical trials, current challenges, and proposals for future development of precision oncology decision support. Clin Cancer Res; 24(12); 2719-31. ©2018 AACR. ©2018 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29420224 PMCID： PMC6004235 DOI： 10.1158/1078-0432.CCR-17-2494
Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531